Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model
Authors:
Open Access
- 27 May 2016
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 68 (7) , 862-872
Abstract
Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and affects approximately 10 million people worldwide. Currently available drugs are not ideal due to high cost, toxicity, parenteral administration and suboptimal efficacy. Miltefosine is the only oral treatment (Impavido®) available to treat CL, given over a period of 28 days with common side effects such as vomiting and diarrhoea. Objective: To explore the local application of miltefosine as a topical formulation to enhance activity and reduce the drug's adverse effects. Methods: The antileishmanial activity of miltefosine was confirmed in vitro against several Leishmania species. The permeation of miltefosine, in different solvents and solvent combinations, through BALB/c mouse skin was evaluated in vitro using Franz diffusion cells. The topical formulations which enabled the highest drug permeation or skin disposition were tested in vivo in BALB/c mice infected with L. major. Key findings: The overall permeation of miltefosine through skin was low regardless of the solvents used. This was reflected in limited antileishmanial activity of the drug formulations when applied topically in vivo. All topical formulations caused skin irritation. Conclusions: We conclude that miltefosine is not an appropriate candidate for the topical treatment of CL.Keywords
Funding Information
- Bloomsbury colleges PhD studentship
This publication has 42 references indexed in Scilit:
- Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in NepalTropical Medicine & International Health, 2012
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Estudo clínico randomizado comparando antimoniato de meglumina, pentamidina e anfotericina B para o tratamento da leishmaniose cutânea ocasionada por Leishmania guyanensisAnais Brasileiros de Dermatologia, 2011
- Efficacy of Miltefosine for Bolivian Cutaneous LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2008
- Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 2007
- Oral miltefosine for the treatment of Indian visceral leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Chemotherapy in the Treatment and Control of Leishmaniasis2006
- THE SENSITIVITY OF CLINICAL ISOLATES OF LEISHMANIA FROM PERU AND NEPAL TO MILTEFOSINEThe American Journal of Tropical Medicine and Hygiene, 2005
- Leishmaniasis: current situation and new perspectivesComparative Immunology, Microbiology and Infectious Diseases, 2004
- Miltefosine for New World Cutaneous LeishmaniasisClinical Infectious Diseases, 2004